May 29th 2025
Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
Exploring the Benefits and Risks of AI in Oncology
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Go To PER in Chicago
May 30, 2025 - June 3, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
Contextualizing Advances in Relapse Refractory DLBCL: Navigating Biomarkers, Emerging Data, and Adverse Event Management to Transform Patient Care
View More
Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma
View More
Biomarkers in Diffuse Large B-Cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes
View More
Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Current Options and Emerging Approaches
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?
View More
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Burst CME™: How is the Newly Approved CAR T-Cell Therapy Impacting R/R B-Cell ALL Management?
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases
View More
Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma
View More
Antisense Inhibits Ewing's Sarcoma in Mice
May 1st 1995NEW ORLEANS--A novel therapy, based on antisense RNA technology, targets aberrant fusion products produced by chromosomal translocations and may lead to the loss of tumorigenicity in tumor cells of the Ewing's sarcoma family, a study from Thomas Jefferson University has shown.
New VIG Regimen Is Called Highly Active in Sarcoma
May 1st 1995LISBON, Portugal--A new regimen that employs escalating doses of etoposide (VePesid) and ifosfamide (Ifex), together with G-CSF (Neupogen), appears to be among the most active combinations tested to date in adult soft-tissue sarcoma, according to a report from the Scandinavian Sarcoma Group
Probable New Herpesvirus Linked to Kaposi's Sarcoma
April 1st 1995The 20-year search for an infectious agent associated with Kaposi's sarcoma (KS) may be over. Researchers at Columbia-Presbyterian Medical Center in New York have reported significant evidence directly linking a probable new herpesvirus to
ODAC Recommends Accelerated Approval of Liposomal Doxorubicin for Kaposi's Sarcoma
April 1st 1995ROCKVILLE, Md--After hours of heated debate, the FDA's Oncologic Drugs Advisory Committee (ODAC) decided there was sufficient evidence of efficacy to recommend approval of DOX-SL (pegylated liposomal doxorubicin) for the treatment of AIDS-related Kaposi's sarcoma (KS) in patients who have failed first-line treatment or who cannot tolerate other treatment. The potential benefits of the drug generally outweigh the risks, the committee said.
Commentary (Healey): Current Combined Treatment of High-Grade Osteosarcomas
April 1st 1995There are few success stories in solid tumor oncology that match osteogenic sarcoma. Drs. Damron and Pritchard have chronicled this story, and present a multidisciplinary overview of the current management of conventional osteogenic sarcoma.
Commentary (Rosen/Forscher): Current Combined Treatment of High-Grade Osteosarcomas
April 1st 1995In this issue of ONCOLOGY, Damron and Pritchard discuss combined therapy for high-grade osteosarcoma. This is a nice review of the current status of osteogenic sarcoma, certainly from the point of view of modern surgical management, and for
Viral Origin of KS Appears Confirmed
March 1st 1995WASHINGTON--New research presented at the 2nd National Conference on Human Retroviruses and Related Infections appears to confirm last year's report that a virus is the cause of Kaposi's sarcoma (KS). Its discoverers, Drs. Patrick S. Moore and Yuan Chang of Columbia University, are calling the virus Kaposi sarcoma-associated herpesvirus (KSHV).
Liposomal Tretinoin in Phase II/III Trials in Kaposi's Sarcoma Patients
February 1st 1995CAMBRIDGE, Mass--Genzyme Corporation and Argus Pharmaceuticals, Inc. (The Woodlands, Texas) are cosponsoring a phase II/III clinical trial of TretinoinLF in Kaposi's sarcoma patients. TretinoinLF is Argus' intravenous liposomal formulation of all-trans-retinoic acid.